在这里，我们介绍了在韩国国家癌症中心接受造血干细胞移植 (HSCT) 的四名 COVID-19 患者的结果。尽管人们担心 HSCT 受者的 COVID-19 病程不利，但我们的患者均未出现严重的 COVID-19 症状。此外，案例 1 中病毒脱落时间延长，持续超过 100 天，在成功植入后得到解决。当宿主无法产生足够的免疫反应时感染病毒可能会导致相反的有利过程。针对 COVID-19 的疫苗接种、单克隆抗体和抗病毒药物的使用也可能有效。我们建议，如有必要，COVID-19 患者不应推迟 HSCT。版权所有 © 2024。由 Elsevier Ltd 出版。

Here, we present the outcomes of four patients with COVID-19 who underwent hematopoietic stem cell transplantation (HSCT) at the National Cancer Center in South Korea. Despite concerns of unfavorable course of COVID-19 in HSCT recipients, none of our patients experienced severe COVID-19. Moreover, extended viral shedding in Case 1, lasting over 100 days, resolved after successful engraftment. Contracting the virus when host could not mount an enough immune reaction might result in paradoxically favorable course. Vaccination, monoclonal antibodies, and antiviral agent usage against COVID-19 might also be effective. We suggest, if necessary, HSCT should not be deferred in COVID-19 patients.Copyright © 2024. Published by Elsevier Ltd.